Skip to main content
HR 3199 116th Congress House Commerce Congressional oversight Department of Commerce Evidence and witnesses Government studies and investigations Intellectual property Prescription drugs

Term Act of 2019

Introduced: June 11, 2019 Introduced by: Jeffries, Hakeem S. Democratic · New York See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 28, 2019
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Jun 11, 2019
Introduced in House
Jun 11, 2019
Referred to the House Committee on the Judiciary.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Terminating the Extension of Rights Misappropriated Act of 2019 or the Term Act of 2019

This bill addresses double patenting with respect to drug-related patents. Specifically, the bill requires an owner of drug-related patents, if the owner lists more than one patent as covering a particular drug, to prove in certain proceedings that each patent covers a distinct invention. If the patent owner fails to do so, then the owner shall have disclaimed patent protection from all the listed patents after the first patent expires.

This requirement shall apply to various proceedings challenging the validity of drug-related patents, as well as to infringement lawsuits filed by the patent owner against companies seeking Food and Drug Administration approval for generic or biosimilar versions of patented drugs.

The bill also directs the U.S. Patent and Trademark Office (USPTO) to review its examination procedures to prevent granting multiple patents for the same drug or biological product, unless the patents cover distinct inventions. The USPTO shall report to Congress its findings and recommendations from the review.

What's happening now June 28, 2019

Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 3
All 3 Republican 2
R
Roy, Chip
Texas · Jul 30, 2019
 R
Cline, Ben
Virginia · Jun 11, 2019
Collins, Doug
· Jun 11, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3199: Term Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-3199/
MLA
"H.R. 3199: Term Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-3199/.
Bluebook (legal)
H.R. 3199, 116th Cong. (2026), https://openamerica.io/bill/116-HR-3199/.
Markdown link
[H.R. 3199: Term Act of 2019](https://openamerica.io/bill/116-HR-3199/)
Report a problem